THOMSON MEDICAL GROUP LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration No. 199908381D)

UPDATE AND UPSIZE OF THE MULTICURRENCY DEBT ISSUANCE PROGRAMME (THE "PROGRAMME") FROM S$500,000,000 TO S$1,000,000,000

The Board of Directors of Thomson Medical Group Limited (the "**Issuer**") wishes to announce that it has on 21 April 2023 completed the update of the Programme established by it on 28 June 2019 to, *inter alia*, (i) amend the ratio of Consolidated Net Debt to Consolidated Total Equity (each as defined in the trust deed dated 28 June 2019, the "**Trust Deed**") set out in the financial covenant under Clause 8.2.2 of the Trust Deed and Condition 4(b)(ii) of the Notes (as defined below) and (ii) amend the notice provisions under the terms and conditions of the Securities (as defined below) such that notices to the holders of the Securities (as defined below) shall also be valid if published on the website of the SGX-ST at http://www.sgx.com. In addition, with effect from 21 April 2023 (the "**Effective Date**"), the maximum aggregate principal amount of notes (the "**Notes**") and perpetual securities (the "**Perpetual Securities**" and, together with the Notes, the "**Securities**") that may be issued under the Programme (the "**Programme Limit**") has been increased from S$500,000,000 to S$1,000,000,000 (the Programme, as amended and updated, the "**Amended Programme**").

DBS Bank Ltd. is the sole arranger and dealer of the Amended Programme.

Under the Amended Programme, the Issuer may, subject to compliance with all relevant laws, regulations and directives from time to time, issue Securities denominated in Singapore dollars or such other currency as may be agreed between the relevant dealers under the Amended Programme and the Issuer.

The Securities will be offered in Singapore pursuant to exemptions invoked under Sections 274, 275 and/or any other applicable provision of the Securities and Futures Act 2001 of Singapore, as modified or amended from time to time.

In connection with the Amended Programme, the Issuer has issued an information memorandum dated 21 April 2023 (the "**Information Memorandum**"), as may be supplemented and/or modified by the applicable pricing supplement or by a supplemental trust deed upon issue of the Securities.

The net proceeds from each issue of Securities under the Amended Programme (after deducting issue expenses) will be used for general corporate purposes of the Issuer and its subsidiaries (the "**Group**"), including refinancing of borrowings, financing potential acquisitions, strategic expansions, general working capital, capital expenditure and other investments of the Group or such purposes as may be specified in the relevant pricing supplement.

Application has been made to the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") for the listing and quotation of any Securities which are agreed at the time of issue thereof to be so listed on the SGX-ST. Such permission will be granted when such Securities have been admitted to the Official List of the SGX-ST. The SGX-ST assumes no responsibility for the correctness of any of the statements made or opinions expressed or reports contained herein. Approval in-principle from, admission to the Official List of the SGX-ST of, and the listing and quotation of any Securities on, the SGX-ST is not to be taken as an indication of the merits of the Issuer, its subsidiaries, its associated companies (if any), the Amended Programme or such Securities.

BY ORDER OF THE BOARD
THOMSON MEDICAL GROUP LIMITED

Dr Heng Jun Li Melvin
Executive Director and Group Chief Executive Officer
21 April 2023